Atlas Molecular Pharma

Atlas Molecular Pharma is a private, preclinical-stage biotech based in Derio, Spain, targeting rare diseases with a proprietary platform called Chassys™. The platform leverages NMR-based technology to design pharmacological chaperones that stabilize misfolded proteins, a common pathogenic mechanism in many rare genetic disorders. The company's lead program, ATL-001, targets Congenital Erythropoietic Porphyria (CEP), and it operates on a capital-efficient, asset-centric licensing model. As a pre-revenue entity, its success hinges on advancing its pipeline through preclinical validation to secure lucrative licensing deals with larger pharmaceutical partners.

Chassys™, an NMR-based proprietary platform for the discovery and optimization of pharmacological chaperones—small molecules designed to stabilize misfolded proteins to treat rare genetic diseases.

Competes with other companies developing pharmacological chaperones (e.g., for lysosomal storage diseases) and with emerging modalities like gene therapy for rare genetic disorders. Its niche focus on ultra-rare diseases and NMR-based platform are key differentiators.